267 related articles for article (PubMed ID: 33552852)
1. Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano-immunotherapy in Breast Cancer Lung Metastasis.
Mpekris F; Panagi M; Voutouri C; Martin JD; Samuel R; Takahashi S; Gotohda N; Suzuki T; Papageorgis P; Demetriou P; Pierides C; Koumas L; Costeas P; Kojima M; Ishii G; Constantinidou A; Kataoka K; Cabral H; Stylianopoulos T
Adv Sci (Weinh); 2021 Feb; 8(3):2001917. PubMed ID: 33552852
[TBL] [Abstract][Full Text] [Related]
2. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
[TBL] [Abstract][Full Text] [Related]
3. A synergistic approach for modulating the tumor microenvironment to enhance nano-immunotherapy in sarcomas.
Mpekris F; Panagi M; Charalambous A; Voutouri C; Michael C; Papoui A; Stylianopoulos T
Neoplasia; 2024 May; 51():100990. PubMed ID: 38520790
[TBL] [Abstract][Full Text] [Related]
4. Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy.
Mpekris F; Voutouri C; Panagi M; Baish JW; Jain RK; Stylianopoulos T
J Control Release; 2022 May; 345():190-199. PubMed ID: 35271911
[TBL] [Abstract][Full Text] [Related]
5. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
6. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
8. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
[TBL] [Abstract][Full Text] [Related]
9. Pirfenidone-Loaded Polymeric Micelles as an Effective Mechanotherapeutic to Potentiate Immunotherapy in Mouse Tumor Models.
Mpekris F; Papaphilippou PC; Panagi M; Voutouri C; Michael C; Charalambous A; Marinov Dinev M; Katsioloudi A; Prokopi-Demetriades M; Anayiotos A; Cabral H; Krasia-Christoforou T; Stylianopoulos T
ACS Nano; 2023 Dec; 17(24):24654-24667. PubMed ID: 38054429
[TBL] [Abstract][Full Text] [Related]
10. Tranilast-induced stress alleviation in solid tumors improves the efficacy of chemo- and nanotherapeutics in a size-independent manner.
Papageorgis P; Polydorou C; Mpekris F; Voutouri C; Agathokleous E; Kapnissi-Christodoulou CP; Stylianopoulos T
Sci Rep; 2017 Apr; 7():46140. PubMed ID: 28393881
[TBL] [Abstract][Full Text] [Related]
11. Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models.
Panagi M; Mpekris F; Chen P; Voutouri C; Nakagawa Y; Martin JD; Hiroi T; Hashimoto H; Demetriou P; Pierides C; Samuel R; Stylianou A; Michael C; Fukushima S; Georgiou P; Papageorgis P; Papaphilippou PC; Koumas L; Costeas P; Ishii G; Kojima M; Kataoka K; Cabral H; Stylianopoulos T
Nat Commun; 2022 Nov; 13(1):7165. PubMed ID: 36418896
[TBL] [Abstract][Full Text] [Related]
12. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
[TBL] [Abstract][Full Text] [Related]
13. Low-dose metronomic gemcitabine pretreatments overcome the resistance of breast cancer to immune checkpoint therapy.
Zheng X; Kuai J; Shen G
Immunotherapy; 2023 Apr; 15(6):429-442. PubMed ID: 36880262
[TBL] [Abstract][Full Text] [Related]
14. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
16. Translational nanomedicine potentiates immunotherapy in sarcoma by normalizing the microenvironment.
Mpekris F; Panagi M; Michael C; Voutouri C; Tsuchiya M; Wagatsuma C; Kinoh H; Osada A; Akinaga S; Yoshida S; Martin JD; Stylianopoulos T
J Control Release; 2023 Jan; 353():956-964. PubMed ID: 36516902
[TBL] [Abstract][Full Text] [Related]
17. Cancer nanomedicine meets immunotherapy: opportunities and challenges.
Sun Q; Bai X; Sofias AM; van der Meel R; Ruiz-Hernandez E; Storm G; Hennink WE; De Geest B; Kiessling F; Yu HJ; Lammers T; Shi Y
Acta Pharmacol Sin; 2020 Jul; 41(7):954-958. PubMed ID: 32555445
[TBL] [Abstract][Full Text] [Related]
18. Bifunctional Therapeutic Peptide Assembled Nanoparticles Exerting Improved Activities of Tumor Vessel Normalization and Immune Checkpoint Inhibition.
Taleb M; Atabakhshi-Kashi M; Wang Y; Rezvani Alanagh H; Farhadi Sabet Z; Li F; Cheng K; Li C; Qi Y; Nie G; Ying Z
Adv Healthc Mater; 2021 Jun; 10(12):e2100051. PubMed ID: 34021735
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
20. Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment.
Wang S; Zhou X; Zeng Z; Sui M; Chen L; Feng C; Huang C; Yang Q; Ji M; Hou P
J Nanobiotechnology; 2021 Oct; 19(1):302. PubMed ID: 34600560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]